Cusi, Kenneth

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 7,239

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 3,476

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 3,100

A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 2,039

Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1

Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., et al. (2003) · Proceedings of the National Academy of Sciences

Metabolism, Diabetes, and CancerAdipose Tissue and Metabolism

Cited by 1,952

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,827

Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle

Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., DeFronzo, R. A., Kahn, C. R., & Mandarino, L. J. (2000) · Journal of Clinical Investigation

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,139

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial

Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 1,024

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,021

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 844

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 757

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPeroxisome Proliferator-Activated Receptors

Cited by 726

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects

Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 629

Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease

Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 618

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 513

High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels

Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 503

A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes

Kashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo, R., & Cusi, K. (2003) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 503

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 455

Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone

Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disorders

Cited by 407

Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling

Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsDiet, Metabolism, and Disease

Cited by 404

Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial

Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 379

Introduction and Methodology: Standards of Care in Diabetes—2023

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Das, S. R., Gibbons, C. H., et al. (2023) · Diabetes Care

Diabetes Management and ResearchDiabetes Management and Education

Cited by 366

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Lomonaco, R., Godinez Leiva, E., Bril, F., Shrestha, S., Mansour, L., Budd, J., Portillo Romero, J., Schmidt, S., Chang, K.-L., Samraj, G., et al. (2021) · Diabetes Care

Liver Disease Diagnosis and TreatmentChronic Kidney Disease and Diabetes

Cited by 354

Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action

Bril, F., & Cusi, K. (2017) · Diabetes Care

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 341